CureVac’s mRNA vaccine is being tested to assess its safety and efficacy in adults of various ages. The trials, which are expected to involve more than 35,000 participants, are taking place in Europe and Latin America.
“With the start of the pivotal Phase 2b/3 study, we have reached another important milestone in the development of our vaccine candidate, CVnCoV,” CureVac CEO Franz-Werner Haas, PhD, said in a news release. “The clinical safety and immunogenicity data achieved to date look promising and we are hopeful that this trial will continue to demonstrate the impact of mRNA technology and our vaccine to prevent COVID-19, and to help defeat this pandemic.”
More articles on COVID-19 vaccines:
US buys 100M more doses of Moderna vaccine
Cardinal Health to distribute COVID-19 vaccines in Ohio
‘Hope on the horizon’: Dr. Maggie Hagan discusses first days of vaccination at Ascension Via Christi
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.